Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.61 |
| ▸ | NAMPT | P43490 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | SPR | P35270 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23791367 | 0.93 | GPR119 (0.59) | GPR119NAMPTKDM4EPKMLMNA | |
| SCHEMBL18714672 | 0.93 | GPR119 (0.59) | GPR119NAMPTKDM4EPKMLMNA | |
| SCHEMBL4325703 | 0.87 | GPR119 (0.58) | GPR119NAMPTKDM4EPKMKDM1A | |
| SCHEMBL8702720 | 0.86 | NAMPT (0.61) | GPR119NAMPTKDM4EPKMLMNA | |
| SCHEMBL2185875 | 0.85 | GPR119 (0.56) | GPR119NAMPTKDM4EPKMKDM1A | |
| SCHEMBL4036422 | 0.85 | GPR119 (0.54) | GPR119KDM4EPKMLMNATP53 | |
| SCHEMBL3923737 | 0.85 | KDM4E (0.64) | GPR119KDM4EPKMLMNATP53 | |
| SCHEMBL22317619 | 0.84 | CYP3A4 (0.52) | MAPTSPRCYP3A4CYP2C9 | |
| SCHEMBL5777274 | 0.84 | NAMPT (0.61) | GPR119NAMPTKDM4EPKMLMNA | |
| SCHEMBL19658651 | 0.83 | SPR (0.55) | PKMSPRCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023046055-A1 | SUBSTITUTED HETEROCYCLIC COMPOUND CONTAINING α-KETONE FRAMEWORK, AND USE THEREOF | 中国药科大学 | 2023-03-30 | — | — | WO | disclosed |
| US-9902712-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-02-27 | — | — | US | disclosed |
| EP-3083584-B1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN THE TREATMENT OF TISSUE FIBROSIS | SUNSHINE LAKE PHARMA CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| CN-104725356-B | Nitrogen heterocyclic derivatives and application thereof in medicine | 广东东阳光药业有限公司 | 2017-02-22 | — | — | CN | disclosed |
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-12-08 | — | — | US | disclosed |
| EP-3083584-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | Sunshine Lake Pharma Co., Ltd. (CN) | 2016-10-26 | — | — | EP | disclosed |
| EP-2358202-B1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| EP-2358202-B1 | BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES | MERCK SHARP & DOHME (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015090232-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-25 | — | — | WO | disclosed |
| CN-104725356-A | Nitrogen heterocyclic derivatives and application thereof in medicine | GUANGDONG HEC PHARMACEUTICAL | 2015-06-24 | — | — | CN | disclosed |
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | TOBIRA THERAPEUTICS, INC. | 2003-06-19 | — | — | US | disclosed |
| US-6562978-B1 | N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2003-05-13 | — | — | US | disclosed |
| CN-1390201-A | cyclic amine compounds as CCR5 antagonists | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2003-01-08 | — | — | CN | disclosed |
| EP-1220842-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | Takeda Chemical Industries, Ltd. (JP) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001025200-A1 | CYCLIC AMINE COMPOUNDS AS CCR5 ANTAGONISTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-12 | — | — | WO | disclosed |
| US-5719166-A | TREATING PSYCHOSES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1998-02-17 | — | — | US | disclosed |
| EP-0532177-B1 | Methanoanthracenes as dopamine antagonists | ZENECA LTD (GB) | 1996-10-16 | — | — | EP | disclosed |
| US-5550136-A | ANTAGONISTS OF DOPAMINE D-2 RECEPTORS | ZENECA LIMITED (GB) | 1996-08-27 | — | — | US | disclosed |
| US-5399568-A | Dopamine antagonists | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-03-21 | — | — | US | disclosed |
| EP-0532177-A1 | Methanoanthracenes as dopamine antagonists | ZENECA LIMITED (GB) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114443-A1 | Cyclic amine compounds as CCR5 antagonists | CCR5, CCR1, CCR3 | GPR119 447/4885NAMPT 3332/4885KDM4E 2791/4885 |
| US-20160355501-A1 | NITROGENOUS HETEROCYCLIC DERIVATIVES AND THEIR APPLICATION IN DRUGS | TNNC1, IAPP, TNNI3 | GPR119 331/4885NAMPT 224/4885KDM4E 4225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.